Anaplastic thyroid cancer (ATC) is an aggressive malignancy with poor survival and limited treated options. Preclinical data suggest a possible therapeutic role for CDK4/6 inhibition. We report our clinical trial with abemaciclib, an oral CDK4/6 inhibitor, in patients with incurable ATC after FDA-approved treatment options. This phase 2 study evaluated the efficacy of oral abemaciclib, 200 mg twice daily.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with S.
Contact S., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack